Adagene Inc. — Regulatory Filings 2021

Aug 12, 2021

6-K 1 tm2124820d1_6k.htm FORM 6-K

Field: Rule-Page

Field: /Rule-Page

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

FORM 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the Month of August 2021

Commission File Number: 001-39997

Field: Rule-Page

Field: /Rule-Page

Adagene Inc.

(Exact Name of Registrant as Specified in Its Charter)

Field: Rule-Page

Field: /Rule-Page

4F, Building C14, No. 218

Xinghu Street, Suzhou Industrial Park

Suzhou, Jiangsu Province, 215123

People’s Republic of China

+86-512-8777-3632

(Address of principal executive offices)

Field: Rule-Page

Field: /Rule-Page

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F x Form 40-F ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S -T Rule 101(b)(1): ¨

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S -T Rule 101(b)(7): ¨

Field: Rule-Page

Field: /Rule-Page

Field: Page; Sequence: 1

Field: /Page

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Adagene Inc.
By:	/s/ Peter (Peizhi) Luo

Title: Chief Executive Officer
Date: August 12, 2021

Field: Page; Sequence: 2

Field: /Page

EXHIBIT INDEX

Exhibit	Description
99.1	Press Release titled
“Adagene Announces Appointment of Interim Chief Medical Officer and New Members of Scientific and Strategic Advisory Board”

Field: Page; Sequence: 3; Options: Last

Field: /Page